                         SEQUENCE LISTING

<110>  SEDERMA
 
<120>  TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC 
       USE

<130>  PEPT JEU 1 PCT

<150>  FR2011742
<151>  2020-11-17

<160>  39    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  1

Lys Thr Thr Lys Ser 
1               5   


<210>  2
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  2

Gly Gln Pro Arg 
1               


<210>  3
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  3

Val Gly Val Ala Pro Gly 
1               5       


<210>  4
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  4

Lys Thr Thr Lys Ser 
1               5   


<210>  5
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  5

Val Gly Val Ala Pro Gly 
1               5       


<210>  6
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyl, R1 = a 1 to 24C, alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  6

Ala Ala Pro Gly 
1               


<210>  7
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyle, R1 =  a 1 to 24C alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  7

Ala Val Pro Gly 
1               


<210>  8
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyle, R1 =  a 1 to 24C alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  8

Val Val Pro Gly 
1               


<210>  9
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyle, R1 =  a 1 to 24C alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  9

Val Ala Pro Gly 
1               


<210>  10
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyle, R1 =  a 1 to 24C alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  10

Ala Pro Gly Ala 
1               


<210>  11
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyl, R1 = a 1 to 24C, alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  11

Ala Pro Gly Val 
1               


<210>  12
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyl, R1 = a 1 to 24C, alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  12

Val Pro Gly Val 
1               


<210>  13
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  the amino acid is either unmodified or modified by acylation 
       -CO-R1, or -SO2-R1 or by a biotinoyle, R1 =  a 1 to 24C alkyl, 
       aryl, aralkyl, alkylaryl, alkoxy, saccharide or aryloxy group

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  the amino acid is either unmodified or modified in OR1, NH2, NHR1
       or NR1R2, R1 and R2 = a 1 to 24C, alkyl, aryl, aralkyl, 
       alkylaryl, alkoxy, saccharide or aryloxy group, R1 and R2 being 
       chosen independently

<400>  13

Val Pro Gly Ala 
1               


<210>  14
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  14

Ala Val Pro Gly 
1               


<210>  15
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  15

Val Pro Gly Ala 
1               


<210>  16
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  16

Arg Ser Arg Lys 
1               


<210>  17
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  17

Gly Gln Pro Arg 
1               


<210>  18
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  18

Lys Thr Phe Lys 
1               


<210>  19
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide

<400>  19

Lys Thr Ala Lys 
1               


<210>  20
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide

<400>  20

Lys Ala Tyr Lys 
1               


<210>  21
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide

<400>  21

Lys Phe Tyr Lys 
1               


<210>  22
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  22

Lys Thr Ser Lys Ser 
1               5   


<210>  23
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa being either a Proline P or a Leucine L

<400>  23

Tyr Gly Gly Phe Xaa 
1               5   


<210>  24
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  24

Gly Lys Thr Thr Lys Ser 
1               5       


<210>  25
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa being Trp, Phe, Tyr, Tic, 7-hydroxy-Tic or Tpi

<400>  25

His Leu Asp Ile Ile Xaa 
1               5       


<210>  26
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Elaidoyl chain on the N terminal end

<400>  26

Lys Thr Phe Lys 
1               


<210>  27
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Elaidoyl chain on the N terminal end

<400>  27

Lys Thr Ala Lys 
1               


<210>  28
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Elaidoyl chain on the N terminal end

<400>  28

Lys Ala Tyr Lys 
1               


<210>  29
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Elaidoyl chain on the N terminal end

<400>  29

Lys Phe Tyr Lys 
1               


<210>  30
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  30

Lys Thr Phe Lys 
1               


<210>  31
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  31

Lys Thr Ser Lys Ser 
1               5   


<210>  32
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa being either a Proline P or a Leucine L.

<400>  32

Tyr Gly Gly Phe Xaa 
1               5   


<210>  33
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<400>  33

Gly Lys Thr Thr Lys Ser 
1               5       


<210>  34
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  amidation by a Palmitoyl chain on the N terminal end

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa being Trp, Phe, Tyr, Tic, 7-hydroxy-Tic or Tpi

<400>  34

His Leu Asp Ile Ile Xaa 
1               5       


<210>  35
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Acetylation on the N-terminal end

<400>  35

Glu Glu Met Gln Arg Arg 
1               5       


<210>  36
<211>  5
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  36

Tyr Ala Gly Phe Leu 
1               5   


<210>  37
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  37

Ala His Ser His 
1               


<210>  38
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  38

Ser Ile Lys Val Ala Val 
1               5       


<210>  39
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic peptide

<400>  39

Gly Pro Gln Gly Pro Gln 
1               5       


